Fatigue syndromes and the aetiology of autoimmune disease

Journal of Chronic Fatigue Syndrome

Volumn 4, Issue 4, 1998, Pages 31-49

  Poteliakhoff, A ^a  

^a NONE   (United Kingdom)

Author keywords

Autoimmune disease; Cortisol; Dehydroepiandrosterone (prasterone); Fatigue syndromes; Immune activation

Indexed keywords

HYDROCORTISONE; PRASTERONE; STEROID;

ARTICLE; AUTOIMMUNE DISEASE; CHRONIC FATIGUE SYNDROME; DISEASE ASSOCIATION; DISEASE COURSE; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; RHEUMATOID ARTHRITIS;

EID: 0032459861     PISSN: 10573321     EISSN: None     Source Type: Journal    
DOI: 10.1300/J092v04n04_04     Document Type: Article

References (73)

1. Jefferies WM. Mild adrenocortical deficiency, chronic allergies, autoimmune disorders and the chronic fatigue syndrome: A continuation of the cortisone story. Medical Hypotheses. 1994; 42: 183-189.
2. Hilgers A and Frank J. Chronic fatigue syndrome: Immune dysfunction, the role of pathogens and toxic agents and neurological and cardiac alterations. Wien med wschr. 1994; 144 (16): 399-406.
3. Demitrack MA, Dale JK, Straus SE et al. Evidence for impaired activation of the Hypothalamic-Pituitary-Adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab. 1991; 73(6): 1224-1234.
4. Poteliakhoff A. Adrenocortical activity and some clinical findings in acute and chronic fatigue. J Psychosom Res. 1981; 25(2): 91-95.
5. Yamaguti K, Kuratsune H, Machi T et al. Abnormality of adrenal function in the patients with CFS: The decline of 17-Ketosteroid sulfate (17-KS-S). J chronic fatigue syndrome. 1996; 2(2/3): 124-25
6. Harrison's Principles of Internal Medicine. 13th ed. New York: Mcgraw-Hill, 1994. p. 1544.
7. Holmes GP, Kaplan JE, Gantz NM et al. Chronic fatigue syndrome: A working case definition. Ann Intern Med. 1988; 108: 387-389.
8. Sharpe M, Archard L, Banatvala J et al. A Report. Chronic Fatigue Syndrome: Guidelines for Research. J Roy Soc Med. 1991; 84: 118-121.
9. Fukuda K, Straus SE, Hickie I et al. The Chronic Fatigue Syndrome: A comprehensive approach to its definition and study. Ann Intern Med. 1994; 121(12): 953-959.
10. Griep EN, Boersma JW, and de Kloet ER. Altered reactivity of the Hypothalamic-Pituitary-Adrenal axis in the Primary Fibromyalgia Syndrome. J Rheumatol. 1993; 20: 469-474.
11. Moldofsky H. Fibromyalgia, sleep disorder and chronic fatigue syndrome. Chronic Fatigue Syndrome. Chichester: Wiley, 1993. 262-279.
12. Dinerman H, Goldenberg DL and Felson DT. A prospective evaluation of 118 patients with the Fibromyalgia Syndrome: prevalence of Raynaud's Phenomenon, Sicca symptoms, ANA, low complement and Ig deposition at the dermal-epidermal junction. J Rheumatol. 1986; 13(2): 368-373.
13. Calabrese LH, Davis ME and Wilke WS. Chronic fatigue syndrome and a disorder resembling Sjogren's syndrome. Clin Infect Dis. 1994; 18 (1): 528-531.
14. Davidson's Principles & Practice of Medicine. 17th ed. Edinburgh: Chuchill Livingstone, 1995. p 45.
15. Roitt I, Brostoff J and Male D. Immunology, 4th ed. London: Mosby, 1996. 27. 1-27. 12.
16. Moos RH and Solomon GF. Studies of rheumatoid arthritis patients. In Modern Trends in Psychosomatic Medicine. 2. London: Butterworth, 1970.
17. Genazzani AR, Nappi G and Petraglia F. Eds. Stress and related disorders: From adaptation to dysfunction. Carnforth, UK: Parthenon, 1991.
18. Selye H. The Physiology and Pathology of Exposure to Stress. Montreal: Acta Inc, 1950.
19. Bauer W and Clark WS. Recent Progress in Endocrine Research. New York, 1953.
20. Solomon GF. Psychoneuroimmunology and chronic fatigue syndrome: Towards new models of disease. J Chronic Fatigue Syndrome. 1995; 1(1): 3-7.
21. Ader R, Cohen N and Felten D. Psychoneuroimmunology: Interaction between the nervous system and the immune system. Lancet. 1995; 345: 99-103.
22. Holmes TH and Rahe RH. The social readjustment rating scale. J Psychosomat Res. 1967; 11: 213-218.
23. Hiemke C, Brunner R, Hammes E et al. Circadian variations in antigen-specific proliferation of human T lymphocytes and correlation to cortisol production. Psychoneuro-endocrinology 1995; 20(3): 335-342.
24. Munck A, Guyre PM and Holbrook NJ. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocrin Rev. 1984; 5(1): 25-44.
25. Reichlin S. Neuroendocrine-immune interactions. New Eng J Med. 1993; 329(17): 1246-1253.
26. Wilder RL, Sternberg EM, Chrousos GP, Wilder RL et al. The stress response and the regulation of inflammatory disease. Ann Inter Med 1992; 117(10): 854-866.
27. Chapel H and Haeney M. Essentials of Clinical Immunology. 3rd ed. Oxford: Blackwell, 1995; 96-98.
28. Roitt IM. Essential Immunology, 8th ed. Oxford: Blackwell, 1994.
29. Report from the National Task Force on Chronic Fatigue Syndrome (CFS) Post Viral Fatigue Syndrome (PVFS) Myalgic Encephalomyelitis (ME). Bristol, UK: Westcare, 1994: p. 20.
30. Chesnokova VM, Chukhlib VL, Ignat'eva EV et al. The possible involvement of glucocorticoids in the development of genetically determined autoimmune pathology in NZB mice. Biomed Science. 1991; 2: 557-561.
31. Neeck G, Federlin K, Graef V et al. Adrenal secretion of cortisol in patients with rheumatoid arthritis. J of Rheumat 1990; 17(1): 24-29.
32. Chikanza IC, Petrou P, Kingsley G et al. Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis and Rheumatism. 1992; 35(11): 1281-1287.
33. Poteliakhoff A. Letter. Emotion and Immunity. Lancet 1985; II: p. 327.
34. Hermann E, Yu DTY, Karl-Hermann Meyer zum Buschenfelde et al. HLA-B27 restricted CDS T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet. 1993; 342: 646-650.
35. Bell DS. Children with Myalgic Encephalomyelitis/Chronic Fatigue Immune Dysfunction Syndrome: Overview and review of the literature. p. 209. In Hyde BM ed. The Clinical and Scientific Basis of ME and CFS. Ottawa: The Nightingale Research Foundation, 1992.
36. Gupta S and Vayuvegula B. A comprehensive immunological analysis in CFS. Scand J Immunol. 1991; 33(3): 319-327.
37. Levy JA. Viral studies of chronic fatigue syndrome. Clin Infect Dis. 1994; 18 (S1): 5117-120.
38. Swanink CM, Vercoulen JH, Galama JM et al. Lymphocyte subsets, apoptosis, and cytokines in patients with chronic fatigue syndrome. J Infect Dis. 1996; 173 (2): 460-463.
39. Barker E, Fujimura SF, Fadem MB et al. Immunologic abnormalities associated with chronic fatigue syndrome. Clin Infect Dis. 1994; 18 (S1): 5136-5141.
40. Buchwald D, Cheyney PR, Peterson DL et al. A chronic illness characterised by fatigue, neurologic and immunologic disorders and active human herpes type 6 infection. Ann Intern Med. 1992; 116(2): 103-113.
41. Klimas NG, Salvato FR, Morgan R et al. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol. 1990; 28(6): 1403-10.
42. Straus SE, Fritz S, Dale JK et al. Lymphocyte phenotype and function in the chronic fatigue syndrome. J Clin Immunol. 1993; 13(1): 30-40.
43. Ojo-Amaize EA, Conley EJ, Peter JB. Decreased Natural Killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome. Clin Infect Dis. 1994; 18 (S1): 3157-3159.
44. Tirelli U, Marotta G, Improta S et al. Immunological abnormalities in patients with chronic fatigue syndrome. Scand J Immunol. 1994; 40(6): 601-608.
45. Linde A, Andersson B, Svenson SB et al. Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J Infect Dis. 1992; 165(6): 994-1000.
46. Patarca R, Klimas NJ, Lugtendorf S et al. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: Interrelations with cellular sources and patterns of soluble immune mediator expression. Clin Infect Dis. 1994; 18 (supp 1): 5147-5153.
47. Rasmussen AK, Nielsen H, Andersen V et al. Chronic fatigue syndrome-a controlled cross sectional study. J Rheumatol. 1994; 21(8): 1527-1531.
48. Chao CC, Janoff EN, Hu SX et al. Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome. Cytokine. 1991; 3(4): 292-298.
49. Buchwald D. In Jenkins R and Mowbray J. (Eds). Postviral Fatigue Syndrome. Chichester: Wiley, 1991: p. 118.
50. Konstantinov K, Von Mikeez A, Buchwald D et al. Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome. J Clin Invest. 1996(8): 1888-1896.
51. Keller RH, Lane JL, Klimas N et al. Association between HLA Class II antigens and the chronic fatigue immune dysfunction syndrome. Clin Infect Dis. 1994; 18 (suppl 1): 5154-5156.
52. Bates DW, Buchwald D, Lee J et al. Laboratory abnormalities in patients with chronic fatigue syndrome. Clin Infect Dis. 1994; 18 (S1): 586.
53. Tirelli U, Tavio M and Pinto A. Immunologic abnormalities in chronic fatigue syndrome. J Chronic Fatigue Syndrome. 1996; 2 (2/3): 88-89.
54. Cheney PR. Evidence of T-cell activation by soluble IL-2-R and TS-R in CFS. In Hyde, op cit., p 621.
55. Flechtner JJ, Miller DR and Sternberg VI. Control of rheumatoid arthritis with low dose prednisone: A patient initiated flare-response regimen. Arth Rheum. 1991; 34 (suppl): S128.
56. Takasu N, Komiya Z, Nagasawa Y et al. Exacerbation of autoimmune thyroid dysfunction after unilateral adrenalectomy in patients with Cushing's syndrome due to an adrenocortical adenoma. New Eng J Med. 1990; 322: 1708-1712.
57. Disdier E, Harle JR, Brue T et al. Severe fibromyalgia after hypophysectomy for Cushing's disease. Arthritis and Rheum. 1997; 34: 493-495.
58. Copeman WSC, Savage O, Bishop PMF et al. A study of cortisone and other steroids in rheumatoid arthritis. Brit Med J. 1950; 2: 1-8.
59. A. Ann N Y Acad Sc. 1995; 774: 47-58.
60. Hornsby PJ. Biosynthesis of DHEAS by the human adrenal cortex and its age-related decline. Ann NY Acad Sc. 1995; 774: 29-46.
61. Berne RM and Levy MN. Physiology. St. Louis: Mosby, 1988: p. 969.
62. Yen SSC, Morales AJ and Khorram O. Replacement of DHEA in aging men and women. Ann NY Acad Sc. 1995; 774: 128-142
63. Meikle AW, Dorchuck RW, Araneo BA et al. The presence of DHEA-specific receptor binding complex in murine T cells. J Steroid Biochem Molec Biol. 1992; 42(3/4): 293-304.
64. Kovacs WJ, Olsen NJ. Androgen receptors in human thymocytes. J Immunol. 1987; 139: 490-493.
65. Padgett DA, Sheridan JF and Loria RM. Steroid hormone regulation of a polyclonal Th2 immune response. Ann NY Acad of Sc. 1995; 774: 323-325.
66. Suitters AJ, Shaw S, Wales MR et al. Immune enhancing effects of dehydroepiandrosterone and dehydroepiandrosterone sulphate and the role of steroid sulphatase. Immunology. 91: 314-321.
67. Araneo BA, Shelby J, Li Q-Z et al. Administration of dehydroepiandrosterone to burned mice preserves normal immunologic competence. Arch Surg. 1993; 128: 318-325.
68. Van Vollenhoven RF and McGuire JL. Studies of dehydroepiandrosterone (DHEA) as a therapeutic agent in systemic lupus erythematosus. Annales de Medicine. 1996; 147(4): 290-296.
69. Suzuki N, Suzuki T and Sakane T. Hormones and Lupus: Defective dehydroepiandrosterone activity induces impaired interleukin-2 activity of T lymphocytes in patients with systemic lupus erythematosus. Annales de Medicine Internl. 1996; 147(4): 248-252.
70. Jungers P, Nahoul K, Pellissier C et al. Low plasma androgen levels in women with active or quiescent SLE. Arthr Rheum. 1982; 25(4): 454-457.
71. Spencer NFL, Poynter ME, Hennebold JD et al. Does DHEAS restore immune competence in aged animals through its capacity to function as a natural modulator of Peroxisome activities? Ann NY Acad of Sc. 1995; 774: 200-216.
72. Van Vollenhoven RF, Engleman EG and McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double blind controlled, randomized clinical trial. Arthritis and Rheumatism. 1995; 38(12): 1826-1831.
73. Sewell KL and Trentham DE. Pathogenesis of rheumatoid arthritis. Lancet. 1993; 341: 283.